Provoked Vestibulodynia is chronic and distressing genital pain which is known as vestibule provoked by touch and sexual activity. Provoked vestibulodynia is most prevalent cause of pain during sexual activity in premenopausal women and insertion of a tampon or speculum which involves sensations of stinging, burning, irritation, and rawness in the area. Provoked vestibulodynia is common and highly treatable, especially with early interventions.
Various treatment options are available for provoked vestibulodynia, such as physiotherapy, psychological interventions, topical and/or oral pain-modulating medication and surgery. Physical and psychological therapies have the best evidence for improved outcome and are recommended as first-line treatment options for provoked vestibulodynia. Provoked vestibulodynia is chronic pain syndrome which tends to remain for years and only treatment relives it. The pain in provoked vestibulodynia usually occurs whenever the pressure is put on the area around the vagina opening.
Many treatment options are used to manage stress, psychological therapies helping women deal with the pain and specific treatment for the pain. If the pain for provoked vestibulodynia last for long than surgery is done to remove the part of area around the vaginal opening which removes the hypersensitive nerve endings. Recent treatment guidelines for provoked vestibulodynia recommend multidisciplinary and individualized care that includes physical, psychological and pharmacological therapies.
Key factors which are driving the growth of provoked vestibulodynia is increasing awareness regarding the diagnosis and treatment at early stages and awareness regarding women healthcare and treatment. Advancement in the healthcare infrastructure and facilities leas to number of treatment options for provoked Vestibulodynia which drive the market for provoked vestibulodynia treatment.
Increased research and development in the wide variety of surgical, medical, behavioral, cognitive-behavioral, and alternative treatments for provoked vestibulodynia spur the market for provoked vestibulodynia treatment market. However some factor restraining the growth of provoked vestibulodynia treatment market are lack of diagnosis resulting in failure for not seeking treatment and stringent regulation by the government.
Provoked vestibulodyniais a common but underdiagnosed chronic pain condition that affects women of all ages. As the exact cause is not available for the disease, mostly symptomatic treatments are used to relieve pain. Research in the novel treatments would provide the edge to the companies for the provoked vestibulodynia treatment market.
Establishment of separate departments by the companies nowadays for women medication products which however would be profitable for the market growth of women healthcare medications Generic availability of the drugs also generates competition among the market players. Easy availability of the drugs is also an advantage for the growth opportunities in provoked vestibulodynia treatment market. Huge opportunity for the provoked vestibulodynia treatment marketis available in the emerging regions where the burden is most acute than the developed markets.
On the basis of geography, the global provoked vestibulodynia treatment market is segmented into seven key regions: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan, and Middle East & Africa. North America is projected to hold the largest share of the global provoked vestibulodynia treatment market owing to high concerns for human health and with the benefit of good reimbursement scenario and government initiatives for healthcare facilities. Western Europe accounts for the second-largest share owing to well-developed healthcare facilities, education and continuous research activities in the medical field in the provoked vestibulodynia treatment market.
The Asia Pacific region is expected to be the fastest-growing region owing to an increase in healthcare expenditure, as well as growing healthcare facilities in the public as well as private sector leads to the growth of provoked vestibulodyniatreatment market over the region. Lack of awareness and healthcare facilities in most parts of Middle East and Africa region leads to their least contribution in the overall global market for provoked vestibulodynia treatment.
Some of the key players present in the global provoked vestibulodynia treatment market are LGM Pharma, Pfizer Inc.,Fresenius Kabi,APP Pharmaceuticals, LLC, Zydus Pharmaceuticals Usa, Inc., Baxter Laboratories, Teva Pharmaceutical Industries Ltd, Mylan N.V., Johnson & Johnson among others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The global provoked vestibulodynia treatment market is segmented by drug type, route of administration and distribution channel:
Segmentation by drug type:
Segmentation by Route of Administration :
Segmentation by Distribution Channel:
Explore Similar Insights
Provoked Vestibulodynia Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
